BioSpace News Archive

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax ® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.

Bone Biologics Corporation today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors.

Pressure BioSciences Signs Definitive Agreement to Acquire Uncle Bud’s, Forward Integrating PBIO’s UltraShear Platform into Multiple Markets.

Indapta Therapeutics, Inc. today announced that the company has initiated treatment of the first patients in its Phase 1 trial in multiple myeloma and Non-Hodgkin’s lymphoma.

Elicio Therapeutics, Inc. today announced that the first patient has been dosed at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research, New York, as part of the randomized Phase 2 (AMPLIFY-7P) study of ELI-002 7P as an adjuvant monotherapy in KRAS mutated pancreatic ductal adenocarcinoma (“PDAC”).

DarioHealth Corp., a leader in the global digital health market, announced a new contract to provide its cardiometabolic solution to a regional union, expected to begin in the first quarter of 2024.

CB Scientific. Inc. today is providing its shareholders with a 2023 year-end review from Charles Martin, Chief Executive Officer.

Resverlogix Corp. (TSX: RVX) (“Resverlogix”, “the Company”) today announced publication of an article, entitled, “The BET inhibitor apabetalone decreases

USAntibiotics today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs.

Autonomix Medical, Inc. announced the completion of its engineering development team formation and provided an engineering update.